MX2019000529A - Proteina de suministro cerebral. - Google Patents
Proteina de suministro cerebral.Info
- Publication number
- MX2019000529A MX2019000529A MX2019000529A MX2019000529A MX2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A
- Authority
- MX
- Mexico
- Prior art keywords
- brain
- brain delivery
- protein
- binding antibody
- present
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 210000004556 brain Anatomy 0.000 title abstract 3
- 230000008499 blood brain barrier function Effects 0.000 abstract 2
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 2
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000005171 mammalian brain Anatomy 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a una proteína de suministro cerebral, que comprende un anticuerpo de unión al objetivo que se une a un objetivo que se une a un objetivo en el cerebro de un mamífero; dos restos portadores, cada uno de los cuales es capaz de una interacción monovalente con una proteína expresada en una célula endotelial de la barrera hematoencefálica (BHE), en donde cada uno de dichos restos portadores está unido a un extremo C-terminal del anticuerpo de unión al objetivo. La presente invención se refiere además al uso de tales proteínas de suministro cerebral en la terapia o el diagnóstico, o para la investigación de, por ejemplo, trastornos neurodegenerativos, y otras enfermedades cerebrales.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1651065 | 2016-07-14 | ||
| PCT/EP2017/067727 WO2018011353A1 (en) | 2016-07-14 | 2017-07-13 | Brain delivery protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000529A true MX2019000529A (es) | 2020-01-15 |
Family
ID=59593007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000529A MX2019000529A (es) | 2016-07-14 | 2017-07-13 | Proteina de suministro cerebral. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11498974B2 (es) |
| EP (1) | EP3484918A1 (es) |
| JP (2) | JP2019529345A (es) |
| KR (1) | KR20190039696A (es) |
| CN (1) | CN109476728A (es) |
| AU (1) | AU2017297804A1 (es) |
| BR (1) | BR112019000098A2 (es) |
| CA (1) | CA3028035A1 (es) |
| IL (1) | IL263773A (es) |
| MA (1) | MA45684A (es) |
| MX (1) | MX2019000529A (es) |
| PH (1) | PH12018502451A1 (es) |
| RU (1) | RU2019102746A (es) |
| SG (2) | SG10201912842VA (es) |
| WO (1) | WO2018011353A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| PT3583120T (pt) | 2017-02-17 | 2022-12-15 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
| CA3118692A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
| MX2022012635A (es) * | 2020-04-08 | 2023-01-11 | Aliada Therapeutics Inc | Composiciones y métodos para distribución de barrera hematoencefálica. |
| US20240141027A1 (en) | 2021-06-11 | 2024-05-02 | Bioarctic Ab | Bispecific binding molecule |
| CA3242212A1 (en) * | 2021-12-31 | 2023-07-06 | Imnewrun Inc | Blood-brain barrier permeable fusion protein and uses thereof |
| WO2023215697A1 (en) * | 2022-05-05 | 2023-11-09 | Eli Lilly And Company | Multispecific binding molecules and methods of use thereof |
| WO2024080843A1 (ko) * | 2022-10-14 | 2024-04-18 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
| KR20240087579A (ko) * | 2022-12-08 | 2024-06-19 | 주식회사 아델 | 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도 |
| KR20250160363A (ko) | 2023-03-24 | 2025-11-12 | 바이오악틱 에이비 | 인간 트랜스페린 수용체 htfr1의 프로테아제-유사 도메인에 결합하는 항체 |
| WO2024263567A2 (en) * | 2023-06-21 | 2024-12-26 | Eli Lilly And Company | Compounds for the delivery of granulin across the blood brain barrier |
| WO2025007703A1 (en) * | 2023-07-04 | 2025-01-09 | Beijing Neox Biotech Limited | Anti-tfr1 antibodies and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| BRPI0709050B1 (pt) | 2006-03-23 | 2018-12-26 | Bioarctic Neuroscience Ab | anticorpo ou fragmento do mesmo, composição, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo |
| WO2008022349A2 (en) * | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| HRP20140783T1 (hr) | 2008-04-24 | 2014-09-12 | Bristol-Myers Squibb Company | Uporaba epotilona d u lijeäśenju tau-povezanih bolesti ukljuäśujuä†i alzheimerovu bolest |
| JP5747414B2 (ja) | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
| CN104800147A (zh) | 2008-07-10 | 2015-07-29 | 德勒尼克斯治疗股份公司 | 用于大分子的增强的递送的方法和组合物 |
| PT2448968T (pt) | 2009-06-29 | 2021-04-30 | Bioarctic Ab | ANTICORPOS SELETIVOS PARA PROTOFIBRILAS/OLIGÓMEROS DE ß- AMILOIDE TRUNCADA EM N-TERMINAL |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| ES2687706T3 (es) | 2010-06-17 | 2018-10-26 | Trellis Bioscience, Llc | Anticuerpos útiles en la inmunización pasiva contra la gripe |
| EA034333B1 (ru) | 2010-11-30 | 2020-01-29 | Дженентек, Инк. | Варианты антитела для переноса соединения через гематоэнцефалический барьер |
| CA2879496C (en) * | 2012-08-29 | 2024-01-09 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
| US9475874B2 (en) * | 2013-08-26 | 2016-10-25 | MabVax Therapeutics, Inc. | Nucleic acids encoding human antibodies to sialyl-lewisa |
| WO2015155694A1 (en) * | 2014-04-08 | 2015-10-15 | Prothena Biosciences Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| SI3166970T1 (sl) * | 2014-07-10 | 2021-09-30 | Bioarctic Ab | Izboljšana A-beta protofibril vezavna protitelesa |
-
2017
- 2017-07-13 AU AU2017297804A patent/AU2017297804A1/en not_active Abandoned
- 2017-07-13 RU RU2019102746A patent/RU2019102746A/ru not_active Application Discontinuation
- 2017-07-13 SG SG10201912842VA patent/SG10201912842VA/en unknown
- 2017-07-13 EP EP17751619.2A patent/EP3484918A1/en not_active Withdrawn
- 2017-07-13 CN CN201780042832.1A patent/CN109476728A/zh active Pending
- 2017-07-13 CA CA3028035A patent/CA3028035A1/en not_active Abandoned
- 2017-07-13 US US16/317,156 patent/US11498974B2/en active Active
- 2017-07-13 SG SG11201810801QA patent/SG11201810801QA/en unknown
- 2017-07-13 KR KR1020197002785A patent/KR20190039696A/ko not_active Ceased
- 2017-07-13 BR BR112019000098-4A patent/BR112019000098A2/pt not_active Application Discontinuation
- 2017-07-13 JP JP2019501707A patent/JP2019529345A/ja active Pending
- 2017-07-13 WO PCT/EP2017/067727 patent/WO2018011353A1/en not_active Ceased
- 2017-07-13 MX MX2019000529A patent/MX2019000529A/es unknown
- 2017-07-13 MA MA045684A patent/MA45684A/fr unknown
-
2018
- 2018-11-21 PH PH12018502451A patent/PH12018502451A1/en unknown
- 2018-12-17 IL IL263773A patent/IL263773A/en unknown
-
2022
- 2022-06-30 JP JP2022106495A patent/JP7589194B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017297804A1 (en) | 2019-01-24 |
| MA45684A (fr) | 2019-05-22 |
| WO2018011353A1 (en) | 2018-01-18 |
| PH12018502451A1 (en) | 2019-09-30 |
| JP2019529345A (ja) | 2019-10-17 |
| JP7589194B2 (ja) | 2024-11-25 |
| KR20190039696A (ko) | 2019-04-15 |
| US20190225699A1 (en) | 2019-07-25 |
| CA3028035A1 (en) | 2018-01-18 |
| JP2022130646A (ja) | 2022-09-06 |
| SG10201912842VA (en) | 2020-02-27 |
| CN109476728A (zh) | 2019-03-15 |
| RU2019102746A (ru) | 2020-08-14 |
| SG11201810801QA (en) | 2019-01-30 |
| BR112019000098A2 (pt) | 2019-04-09 |
| EP3484918A1 (en) | 2019-05-22 |
| RU2019102746A3 (es) | 2020-11-30 |
| IL263773A (en) | 2019-02-28 |
| US11498974B2 (en) | 2022-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502451A1 (en) | Brain delivery protein | |
| PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
| WO2015031673A3 (en) | Cns-targetedconjugates of antibodies | |
| BR112018010084A2 (pt) | ligantes de pd1 e/ou lag3 | |
| DOP2018000125A (es) | Proteínas de unión a ctla4p | |
| EA201490745A1 (ru) | Полипептиды антител, которые вызывают антагонизм cd40l | |
| HK1254861A1 (zh) | 抗lag3抗体及其用途 | |
| JO3658B1 (ar) | بروتينات اندماج | |
| PE20171336A1 (es) | Anticuerpos contra tau y sus usos | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| EP4406612A8 (en) | Anti-cd70 antibody drug conjugates | |
| UA118029C2 (uk) | Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування | |
| PH12014501083A1 (en) | Anticancer fusion protein | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| MX384984B (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| UA118286C2 (uk) | Білок агоніст рецептора trail | |
| AU2018249796A1 (en) | Antibody Fc variants for improving blood half-life | |
| PH12014501363A1 (en) | Anticancer fusion protein | |
| PL393578A1 (pl) | Przeciwnowotworowe białko fuzyjne | |
| MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
| MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
| MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| PL394618A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| AU2018281871A1 (en) | Vascular endothelial growth factor/anti-fibronectin antibody fusion proteins |